Cytoagents Inc.
Pittsburgh, PA
- UEI
- CCEZCKNKL9M4
- CAGE
- 8CQA6
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 100 S Commons #102, Pittsburgh, PA 15212, USA
- Website
- cytoagents.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Signablok, Inc. | Worcester, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Kevirx Inc. | Charlottesville, VA | — |
About the company
Cytoagents Inc. is a for-profit corporate entity based in Pittsburgh, Pennsylvania, registered in the System for Award Management (SAM) since July 2019. The company focuses on developing pharmaceutical compounds that modulate inflammatory responses, with a particular emphasis on innovative treatments for complex medical conditions. Its primary research appears centered on developing immunomodulatory agents designed to mitigate severe inflammatory responses in various medical contexts.
The company has secured multiple federal grant awards from key research agencies, specifically the National Cancer Institute and the National Institute of Allergy and Infectious Diseases. These grants have supported the preclinical development of compounds like CTO1681 and GP1681, which are designed to address critical medical challenges such as cytokine release syndrome (CRS) in CAR T-cell therapy and inflammatory responses in viral infections like COVID-19. The most recent grant, awarded in September 2025 from the National Cancer Institute, provides $1,313,567 to develop CTO1681, a compound aimed at preventing and treating cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy. Previous grants have focused on developing immunomodulatory agents to regulate inflammatory responses, with a specific project from March 2021 targeting SARS-CoV-2 related hypercytokinemia. These research projects demonstrate Cytoagents' commitment to developing targeted therapeutic interventions that can potentially reduce severe inflammatory complications in complex medical treatments.
Quick answers
Is Cytoagents Inc. registered in SAM.gov?
Yes. Cytoagents Inc.'s SAM.gov registration is active through July 13, 2027.
What is Cytoagents Inc.'s CAGE code?
Cytoagents Inc.'s CAGE code is 8CQA6, and its Unique Entity ID (UEI) is CCEZCKNKL9M4.
What is Cytoagents Inc.'s most recent federal award?
Cytoagents Inc.'s most recent federal grant award is CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving car T-cell therapy (R44CA295189), from National Cancer Institute (NIH), on September 22, 2025.
On GovTribe
See Cytoagents Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors